Tag: IL13

Lebrikizumab, an investigational interleukin (IL)-13 inhibitor seeking to join an increasingly crowded market for atopic dermatitis treatments, effectively reduced symptoms of the condition (a.k.a. eczema) when combined with topical corticosteroids, researchers reported. In a randomized trial called ADhere — one of three phase III studies that developers Eli Lilly and Almirall have completed for the […]